• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM
Click for more information
7.02% 30.5¢

IMMUTEP LIMITED - Announcements

Market Cap $486.6M  ! watchlist Created with Sketch. Add to my watchlist

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMM Prima BioMed Files U.S Shelf Registration Statement-PRR.AX PRICE SENSITIVE30/05/16
IMM Investor Update-PRR.AX 12/05/16
IMM PRR Enters Agreement with Sydys to Advance CVac Program-PRR.AX PRICE SENSITIVE12/05/16
IMM Japanese Patent Grants For IMP321 In Cancer-PRR.AX PRICE SENSITIVE02/05/16
IMM Response to ASX Price Query-PRR.AX PRICE SENSITIVE21/04/16
IMM Appendix 4C - quarterly March 2016-PRR.AX PRICE SENSITIVE08/04/16
IMM IMP321 data published in Clinical Cancer Research Journal15/03/16
IMM S&P DJ Indices Announces March Quarterly Review11/03/16
IMM Appointment of Joint Company Secretary08/03/16
IMM Appendix 3B07/03/16
IMM Prima receives NASDAQ deficiency notice04/03/16
IMM First patient dosed in AIPACPRICE SENSITIVE02/03/16
IMM Half Yearly Report and AccountsPRICE SENSITIVE29/02/16
IMM Prima Newsletter11/02/16
IMM US patent granted for IMP731 antibodyPRICE SENSITIVE28/01/16
IMM Prima initiates Phase I melanoma study in AustraliaPRICE SENSITIVE27/01/16
IMM Response to ASX Price QueryPRICE SENSITIVE08/01/16
IMM Appendix 4C - quarterlyPRICE SENSITIVE07/01/16
IMM Appendix 3B29/12/15
IMM Prima initiates phase IIb study in metastatic breast cancerPRICE SENSITIVE22/12/15
IMM Prima Progresses Japanese CollaborationPRICE SENSITIVE11/12/15
IMM $420k R&D Tax Incentive Refund ReceivedPRICE SENSITIVE26/11/15
IMM Results of Meeting25/11/15
IMM 2015 CEO's Presentation25/11/15
IMM 2015 AGM Address to Shareholders25/11/15
IMM Prima Newsletter23/11/15
IMM Prima unveils Phase I combination study of IMP321PRICE SENSITIVE18/11/15
IMM Prima to present at Immune Checkpoint Inhibitor meeting05/11/15
IMM Annual Report filed on Form 20-F with SEC02/11/15
IMM Cleansing Notice & Appendix 3B30/10/15
IMM Prima announces A$2m investment from institutional investorPRICE SENSITIVE30/10/15
IMM Belgian regulatory approval received for AIPAC trialPRICE SENSITIVE27/10/15
IMM Appendix 4G22/10/15
IMM Annual Report to Shareholders22/10/15
IMM Notice of Annual General Meeting/Proxy Form22/10/15
IMM Change of Address19/10/15
IMM Information Required Under Listing Rule 3.10.5A14/10/15
IMM Prima announces A$1.55m investment from NyenburgPRICE SENSITIVE13/10/15
IMM Cleansing Notice & Appendix 3B13/10/15
IMM Prima receives grant from the Saxony Development BankPRICE SENSITIVE09/10/15
IMM Appendix 4C - quarterlyPRICE SENSITIVE08/10/15
IMM Change of Director's Interest Notice02/10/15
IMM Change of Director's Interest Notice02/10/15
IMM Appendix 3B & Cleansing Notice01/10/15
IMM Prima to present at Leerink Partners Rare Disease Roundtable25/09/15
IMM Response to ASX Price QueryPRICE SENSITIVE03/09/15
IMM Prima to present at Rodman & Renshaw Conference28/08/15
IMM Appendix 4E & 2015 Full Year Statutory AccountsPRICE SENSITIVE28/08/15
IMM Milestone payment to be received from NovartisPRICE SENSITIVE14/08/15
IMM Change of Director's Interest Notice05/08/15
IMM Appendix 3B05/08/15
IMM Cleansing Notice04/08/15
IMM Section 708A(12C)(e) Cleansing Notice04/08/15
IMM Appendix 3B04/08/15
IMM Warrants ProspectusPRICE SENSITIVE04/08/15
IMM Termination of Bergen Investment FacilityPRICE SENSITIVE04/08/15
IMM Change of Director's Interest Notice03/08/15
IMM Change of Director's Interest Notice03/08/15
IMM Results of Meeting31/07/15
IMM 2015 EGM CEO's Presentation31/07/15
IMM 2015 EGM Chairman's Address31/07/15
IMM Appendix 3B30/07/15
IMM Appendix 4C - quarterlyPRICE SENSITIVE28/07/15
IMM Prima raises A$10m through Share Purchase Plan24/07/15
IMM Response to ASX Aware LetterPRICE SENSITIVE13/07/15
IMM Share Purchase Plan Offer Documents10/07/15
IMM Prima Newsletter10/07/15
IMM Share Purchase PlanPRICE SENSITIVE07/07/15
IMM Positive scientific advice received from the EMA for IMP321PRICE SENSITIVE07/07/15
IMM Notice of Extraordinary General Meeting/Proxy Form29/06/15
IMM Appendix 3B23/06/15
IMM Cleansing Notice12/06/15
IMM Prima to present at Bioshares Biotech Summit12/06/15
IMM Appendix 3B11/06/15
IMM Prima receives research tax credit cash rebate in France11/06/15
IMM Appendix 3B10/06/15
IMM Appendix 3B05/06/15
IMM Ceasing to be a substantial holder05/06/15
IMM Prima to maintain NASDAQ listing04/06/15
IMM Appendix 3B04/06/15
IMM Cleansing Notice & Appendix 3B03/06/15
IMM Ceasing to be a substantial holder - J.P. Morgan03/06/15
IMM Becoming a substantial holder - J.P. Morgan03/06/15
IMM Appendix 3B02/06/15
IMM Change in substantial holding02/06/15
IMM Appendix 3B29/05/15
IMM Prima announces new IP for IMP 321PRICE SENSITIVE29/05/15
IMM Becoming a substantial holder29/05/15
IMM Appendix 3B28/05/15
IMM Becoming a substantial holder27/05/15
IMM Cleansing Notice & Appendix 3B27/05/15
IMM Appendix 3B26/05/15
IMM Appendix 3B25/05/15
IMM Prima to Present at Proactive Investors Forums25/05/15
IMM Prima to Commercialise Database Management PlatformPRICE SENSITIVE25/05/15
IMM Cleansing Notice20/05/15
IMM Prima May 2015 Corporate Presentation20/05/15
IMM Prima 2015 Capital Raising Presentation20/05/15
IMM CVac shows overall survival benefitPRICE SENSITIVE19/05/15
IMM Change of registry address15/05/15
IMM Prima BioMed Files U.S Shelf Registration Statement-PRR.AX
30/05/16PRICE SENSITIVE
IMM Investor Update-PRR.AX
12/05/16
IMM PRR Enters Agreement with Sydys to Advance CVac Program-PRR.AX
12/05/16PRICE SENSITIVE
IMM Japanese Patent Grants For IMP321 In Cancer-PRR.AX
02/05/16PRICE SENSITIVE
IMM Response to ASX Price Query-PRR.AX
21/04/16PRICE SENSITIVE
IMM Appendix 4C - quarterly March 2016-PRR.AX
08/04/16PRICE SENSITIVE
IMM IMP321 data published in Clinical Cancer Research Journal
15/03/16
IMM S&P DJ Indices Announces March Quarterly Review
11/03/16
IMM Appointment of Joint Company Secretary
08/03/16
IMM Appendix 3B
07/03/16
IMM Prima receives NASDAQ deficiency notice
04/03/16
IMM First patient dosed in AIPAC
02/03/16PRICE SENSITIVE
IMM Half Yearly Report and Accounts
29/02/16PRICE SENSITIVE
IMM Prima Newsletter
11/02/16
IMM US patent granted for IMP731 antibody
28/01/16PRICE SENSITIVE
IMM Prima initiates Phase I melanoma study in Australia
27/01/16PRICE SENSITIVE
IMM Response to ASX Price Query
08/01/16PRICE SENSITIVE
IMM Appendix 4C - quarterly
07/01/16PRICE SENSITIVE
IMM Appendix 3B
29/12/15
IMM Prima initiates phase IIb study in metastatic breast cancer
22/12/15PRICE SENSITIVE
IMM Prima Progresses Japanese Collaboration
11/12/15PRICE SENSITIVE
IMM $420k R&D Tax Incentive Refund Received
26/11/15PRICE SENSITIVE
IMM Results of Meeting
25/11/15
IMM 2015 CEO's Presentation
25/11/15
IMM 2015 AGM Address to Shareholders
25/11/15
IMM Prima Newsletter
23/11/15
IMM Prima unveils Phase I combination study of IMP321
18/11/15PRICE SENSITIVE
IMM Prima to present at Immune Checkpoint Inhibitor meeting
05/11/15
IMM Annual Report filed on Form 20-F with SEC
02/11/15
IMM Cleansing Notice & Appendix 3B
30/10/15
IMM Prima announces A$2m investment from institutional investor
30/10/15PRICE SENSITIVE
IMM Belgian regulatory approval received for AIPAC trial
27/10/15PRICE SENSITIVE
IMM Appendix 4G
22/10/15
IMM Annual Report to Shareholders
22/10/15
IMM Notice of Annual General Meeting/Proxy Form
22/10/15
IMM Change of Address
19/10/15
IMM Information Required Under Listing Rule 3.10.5A
14/10/15
IMM Prima announces A$1.55m investment from Nyenburg
13/10/15PRICE SENSITIVE
IMM Cleansing Notice & Appendix 3B
13/10/15
IMM Prima receives grant from the Saxony Development Bank
09/10/15PRICE SENSITIVE
IMM Appendix 4C - quarterly
08/10/15PRICE SENSITIVE
IMM Change of Director's Interest Notice
02/10/15
IMM Change of Director's Interest Notice
02/10/15
IMM Appendix 3B & Cleansing Notice
01/10/15
IMM Prima to present at Leerink Partners Rare Disease Roundtable
25/09/15
IMM Response to ASX Price Query
03/09/15PRICE SENSITIVE
IMM Prima to present at Rodman & Renshaw Conference
28/08/15
IMM Appendix 4E & 2015 Full Year Statutory Accounts
28/08/15PRICE SENSITIVE
IMM Milestone payment to be received from Novartis
14/08/15PRICE SENSITIVE
IMM Change of Director's Interest Notice
05/08/15
IMM Appendix 3B
05/08/15
IMM Cleansing Notice
04/08/15
IMM Section 708A(12C)(e) Cleansing Notice
04/08/15
IMM Appendix 3B
04/08/15
IMM Warrants Prospectus
04/08/15PRICE SENSITIVE
IMM Termination of Bergen Investment Facility
04/08/15PRICE SENSITIVE
IMM Change of Director's Interest Notice
03/08/15
IMM Change of Director's Interest Notice
03/08/15
IMM Results of Meeting
31/07/15
IMM 2015 EGM CEO's Presentation
31/07/15
IMM 2015 EGM Chairman's Address
31/07/15
IMM Appendix 3B
30/07/15
IMM Appendix 4C - quarterly
28/07/15PRICE SENSITIVE
IMM Prima raises A$10m through Share Purchase Plan
24/07/15
IMM Response to ASX Aware Letter
13/07/15PRICE SENSITIVE
IMM Share Purchase Plan Offer Documents
10/07/15
IMM Prima Newsletter
10/07/15
IMM Share Purchase Plan
07/07/15PRICE SENSITIVE
IMM Positive scientific advice received from the EMA for IMP321
07/07/15PRICE SENSITIVE
IMM Notice of Extraordinary General Meeting/Proxy Form
29/06/15
IMM Appendix 3B
23/06/15
IMM Cleansing Notice
12/06/15
IMM Prima to present at Bioshares Biotech Summit
12/06/15
IMM Appendix 3B
11/06/15
IMM Prima receives research tax credit cash rebate in France
11/06/15
IMM Appendix 3B
10/06/15
IMM Appendix 3B
05/06/15
IMM Ceasing to be a substantial holder
05/06/15
IMM Prima to maintain NASDAQ listing
04/06/15
IMM Appendix 3B
04/06/15
IMM Cleansing Notice & Appendix 3B
03/06/15
IMM Ceasing to be a substantial holder - J.P. Morgan
03/06/15
IMM Becoming a substantial holder - J.P. Morgan
03/06/15
IMM Appendix 3B
02/06/15
IMM Change in substantial holding
02/06/15
IMM Appendix 3B
29/05/15
IMM Prima announces new IP for IMP 321
29/05/15PRICE SENSITIVE
IMM Becoming a substantial holder
29/05/15
IMM Appendix 3B
28/05/15
IMM Becoming a substantial holder
27/05/15
IMM Cleansing Notice & Appendix 3B
27/05/15
IMM Appendix 3B
26/05/15
IMM Appendix 3B
25/05/15
IMM Prima to Present at Proactive Investors Forums
25/05/15
IMM Prima to Commercialise Database Management Platform
25/05/15PRICE SENSITIVE
IMM Cleansing Notice
20/05/15
IMM Prima May 2015 Corporate Presentation
20/05/15
IMM Prima 2015 Capital Raising Presentation
20/05/15
IMM CVac shows overall survival benefit
19/05/15PRICE SENSITIVE
IMM Change of registry address
15/05/15
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
30.5¢ 		Change
0.020(7.02%) 		Mkt cap ! $486.6M
Open High Low Value Volume
29.0¢ 31.0¢ 29.0¢ $1.171M 3.900M

Buyers (Bids)

No. Vol. Price($)
5 101067 30.5¢
 

Sellers (Offers)

Price($) Vol. No.
31.0¢ 8068 2
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
Last
30.5¢ 		  Change
0.020 ( 4.85 %)
Open High Low Volume
29.0¢ 31.0¢ 29.0¢ 1352108
Last updated 15.59pm 22/11/2024 ?
IMM (ASX) Chart

Top Stories

Pan Asia rebranding to 'clear confusion' after bagging $35M for Chile projects

Pan Asia Metals has scored $35 million from a New York private equity firm at the same time as the company's big rebrand push begins.
HotCopper Highlights: Your most watched stocks for Week 47, 2024 In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Sales growth pushes Lovisa's fortunes (and shares) upwards Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.